IDiyas

For the Inventor, By the Inventor

Rockville, MD, United States of America

Vivian Albert

USPTO Granted Patents = 13

Average Co-Inventor Count = 4.2

ph-index = 7

Forward Citations = 373(Granted Patents)


Company Filing History:

goldMedal13 out of 676 
 
Human Genome Sciences, Inc.
 patents

Years Active: 2005-2016

Loading Chart...
13 patents (USPTO):Explore Patents
1. 9403905 - Vascular endothelial growth factor 2 (2016-08-02),
2. 8784809 - Vascular endothelial growth factor 2 (2014-07-22),
3. 8216569 - Vascular endothelial growth factor 2 (2012-07-10),
4. 8206708 - Vascular endothelial growth factor 2 (2012-06-26),
5. 7850963 - Vascular endothelial growth factor 2 (2010-12-14),
6. 7550569 - Antibodies that specifically bind to GMAD (2009-06-23),
7. 7402312 - Antibodies to vascular endothelial growth factor 2 (VEGF-2) (2008-07-22),
8. 7361341 - Methods of treating cancer using antibodies that immunospecifically bind to trail receptors (2008-04-22),
9. 7348003 - Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors (2008-03-25),
10. 7208582 - Vascular endothelial growth factor 2 (2007-04-24),
11. 7109302 - Antibodies that specifically bind to GMAD (2006-09-19),
12. 7064189 - Antibodies that immunospecifically bind to trail receptors (2006-06-20),
13. 6900033 - Methods and compositions for modulating ACE-2 activity (2005-05-31),

Title: **Vivian Albert: Pioneering Innovator in Antibody Therapeutics**

Introduction

Vivian Albert is a distinguished inventor based in Rockville, MD, who has made significant contributions to the field of biotechnology. With a total of 13 patents to her name, she has focused her research on innovative therapeutic solutions, particularly concerning human vascular endothelial growth factor.

Latest Patents

Among her most notable inventions is her latest patent involving human VEGF-2 antibodies, antibody fragments, or variants thereof. This invention details processes for producing such antibodies and outlines methods and compositions aimed at preventing, treating, or ameliorating diseases and disorders in humans through the administration of effective amounts of VEGF-2 antibodies or their fragments and variants. The dual focus on both the composition and the application of these antibodies highlights the potential for significant advancements in medical treatment.

Career Highlights

Vivian has developed her career at Human Genome Sciences, Inc., where her passion for research and innovation in genetic therapies has flourished. Her commitment to advancing healthcare through her inventions showcases her drive and expertise, positioning her as a key figure in her field.

Collaborations

Throughout her career, Vivian has worked alongside notable colleagues such as Craig A. Rosen and Steven M. Ruben. These collaborations have likely contributed to her success and the development of groundbreaking therapies in the biotechnology sector.

Conclusion

Vivian Albert exemplifies the spirit of innovation and perseverance within the scientific community. Her work on VEGF-2 antibodies holds promise for new therapeutic avenues that could improve patient outcomes in the treatment of various diseases. Her innovative contributions continue to inspire and drive forward the field of biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…